Abstract
The problem of comorbidity is recognized as one of the key in modern world medicine, it requires consideration of all interacting factors and risks and coordinated therapy. From a complex of comorbid processes, it is necessary to distinguish clusters of diseases, most often combined with each other or accompanying other diseases, including the musculoskeletal system, widespread, occurring in all age groups of the population and being the leading cause of chronic disability and a significant reduction in the quality of life of patients. Traditional treatment of pain in osteoarthritis is the appointment of a special group of drugs - non-steroidal anti-inflammatory drugs, which have a pronounced positive therapeutic effect, but have a fairly large range of adverse events. In addition, in accordance with modern guidelines for the treatment of OA, among the pharmacological methods, the leading place is occupied by delayed-acting drugs (S YSADOA), including the original biotechnological drug Alflutop.The results of many studies show that Alflutop has an acceptable profile of both gastrointestinal and cardiovascular safety and proven clinical efficacy, which allows it to be chosen for the treatment of patients with various comorbid pathology, which is characteristic of elderly people in particular.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.